Skip to main content
Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A. — Investor Relations & Filings

Ticker · NWRN ISIN · IT0004147952 LEI · 8156002F8C11F80A9740 SW Manufacturing
Open in API
Filings indexed 135 across all filing types
Latest filing 2025-08-12 Regulatory Filings
Country IT Italy
Listing SW NWRN

About Newron Pharmaceuticals S.p.A.

https://www.newron.com/

Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.

Recent filings

Filing Released Lang Actions
EQS-News: Newron beginnt Rekrutierung für zulassungsrelevantes Phase-III-Entwicklungsprogramm ENIGMA-TRS mit Evenamide als Zusatztherapie bei Patienten mit behandlungsresistenter Schizophrenie (TRS)
Regulatory Filings Classification · 100% confidence The document is a corporate news release issued by Newron Pharmaceuticals S.p.A. regarding the commencement of patient recruitment for a Phase III clinical trial (ENIGMA-TRS). It follows the standard format of a press release distributed via EQS News, detailing clinical trial milestones, study design, and forward-looking statements. As it is a corporate announcement regarding business operations and clinical development rather than a formal financial report, audit, or proxy statement, it falls under the category of general regulatory filings/corporate news.
2025-08-12 German
Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Regulatory Filings Classification · 95% confidence The document is a corporate press release issued by Newron Pharmaceuticals announcing the publication of preclinical research findings in a peer-reviewed journal. It provides details on the study's methodology and implications for their drug candidate, evenamide. As it is a corporate news announcement regarding research and development progress rather than a formal financial report, regulatory filing, or investor presentation, it falls under the category of general corporate news/regulatory announcements.
2025-08-11 English
EQS-News: Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Regulatory Filings Classification · 98% confidence The document is a corporate press release issued by Newron Pharmaceuticals S.p.A. regarding the publication of preclinical research findings in a peer-reviewed journal. It details the scientific mechanism of their drug candidate 'evenamide' and its potential impact on schizophrenia treatment. It does not constitute a formal financial report, proxy statement, or regulatory filing, but rather a standard corporate news announcement disseminated via the EQS News service. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate news announcement.
2025-08-11 English
EQS-News: Newron verweist auf die Veröffentlichung neuer präklinischer Forschungsergebnisse, die auf eine Verbesserung schizophreniebedingter Funktionsstörungen durch Evenamide hindeuten
Regulatory Filings Classification · 99% confidence The document is a press release from Newron Pharmaceuticals announcing the publication of new preclinical research results for their drug candidate 'Evenamide' in the journal 'Neuropsychopharmacology'. It details the scientific findings, the mechanism of action, and the implications for their ongoing clinical trials. As this is a corporate announcement regarding research and development progress rather than a formal financial report, a regulatory filing, or a transcript, it falls under the category of general regulatory announcements/news releases.
2025-08-11 German
Newron gibt Genehmigung fur zulassungsrelevantes Phase-III-Entwicklungsprogramm ENIGMA-TRS mit Evenamide als Zusatztherapie bei Patienten mit behandlungsresistenter Schizophrenie (TRS) bekannt
Regulatory Filings Classification · 99% confidence The document is titled 'Ad-hoc' and begins with an announcement regarding the approval of a Phase III development program (ENIGMA-TRS) for a drug (Evenamide). It explicitly states it is an 'Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014' (Insider Information under Article 17 of Regulation (EU) No 596/2014), which is a mandatory disclosure requirement for listed companies in the EU regarding price-sensitive information. This type of immediate, material, non-public information release, often related to clinical trial progress or regulatory milestones, is typically classified as a general regulatory announcement or a specific type of corporate news release that doesn't fit the defined financial report categories (like 10-K, IR, ER). Since it is a specific, material announcement that doesn't match the detailed definitions (like ER for earnings, CT for transcripts, or IP for investor presentations), the most appropriate fallback category for a general regulatory filing/announcement of this nature is 'Regulatory Filings' (RNS). The document length is substantial (9369 chars), so it is not a simple RPA.
2025-05-12 German
EQS-Adhoc: Newron gibt Genehmigung für zulassungsrelevantes Phase-III-Entwicklungsprogramm ENIGMA-TRS mit Evenamide als Zusatztherapie bei Patienten mit behandlungsresistenter Schizophrenie (TRS) ...
Regulatory Filings Classification · 99% confidence The document is titled "Ad hoc-Mitteilung gemäss Art. 53 KR" and explicitly states it is an "Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014" (Insider Information according to Article 17 of Regulation (EU) No 596/2014). This format is characteristic of mandatory regulatory disclosures in the EU/EEA, often related to material non-public information. The content announces the approval for a Phase III clinical trial program (ENIGMA-TRS) for a drug (Evenamide). This type of announcement, which is a material event disclosure but not a full financial report (like 10-K or IR) or a standard earnings release (ER), fits best under the general category for regulatory announcements that don't have a more specific code. While it contains significant business/R&D information, it is primarily a regulatory disclosure of a material event. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a mandatory, ad-hoc regulatory announcement that isn't a specific financial report or management/proxy filing. It is not a Call Transcript (CT), Earnings Release (ER), or a specific financial report (10-K, IR).
2025-05-12 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.